| Primary |
| Breast Cancer |
30.7% |
| Hodgkin's Disease |
10.7% |
| Breast Cancer Stage Iii |
8.0% |
| Non-hodgkin's Lymphoma |
7.3% |
| Plasma Cell Myeloma |
6.0% |
| Malignant Lymphoid Neoplasm |
4.0% |
| Peripheral T-cell Lymphoma Unspecified Stage Iv |
4.0% |
| Cll |
3.3% |
| Diffuse Large B-cell Lymphoma |
3.3% |
| Hodgkin's Lymphoma |
3.3% |
| Prophylaxis |
3.3% |
| Chemotherapy |
2.7% |
| Oestrogen Receptor Assay Positive |
2.7% |
| Bone Sarcoma |
2.0% |
| Gastric Cancer |
2.0% |
| Nephroblastoma |
2.0% |
| B-cell Lymphoma |
1.3% |
| Multiple Myeloma |
1.3% |
| Prophylaxis Of Nausea And Vomiting |
1.3% |
| Adenosquamous Cell Lung Cancer |
0.7% |
|
| Maternal Exposure Timing Unspecified |
12.5% |
| Anaphylactic Shock |
9.4% |
| Deep Vein Thrombosis |
6.3% |
| Hepatocellular Injury |
6.3% |
| Osteonecrosis |
6.3% |
| Pyrexia |
6.3% |
| Second Primary Malignancy |
6.3% |
| Sepsis |
6.3% |
| Vomiting |
6.3% |
| Bacteraemia |
3.1% |
| Cardiac Failure |
3.1% |
| Cardiac Failure Congestive |
3.1% |
| Death |
3.1% |
| Diabetes Mellitus |
3.1% |
| Duodenal Ulcer |
3.1% |
| Febrile Neutropenia |
3.1% |
| Fluid Overload |
3.1% |
| Foetal Death |
3.1% |
| Hepatic Function Abnormal |
3.1% |
| Hepatitis B |
3.1% |
|
| Secondary |
| Hodgkin's Disease |
16.8% |
| Multiple Myeloma |
11.6% |
| Plasma Cell Myeloma |
9.8% |
| Lymphoma |
8.4% |
| Non-hodgkin's Lymphoma |
8.3% |
| Acute Lymphocytic Leukaemia |
5.9% |
| Product Used For Unknown Indication |
5.6% |
| Diffuse Large B-cell Lymphoma |
5.4% |
| Breast Cancer |
4.5% |
| Acute Leukaemia |
3.1% |
| Drug Use For Unknown Indication |
2.8% |
| B-cell Lymphoma |
2.6% |
| Sarcoma |
2.6% |
| Castleman's Disease |
2.3% |
| Malignant Lymphoid Neoplasm |
2.1% |
| Prophylaxis |
1.9% |
| Cervix Carcinoma Stage I |
1.6% |
| Hodgkin's Lymphoma |
1.6% |
| Burkitt's Lymphoma |
1.5% |
| Aesthesioneuroblastoma |
1.5% |
|
| Thrombocytopenia |
13.3% |
| Second Primary Malignancy |
9.6% |
| Toxicity To Various Agents |
7.8% |
| Sepsis |
7.2% |
| Hodgkin's Disease |
6.6% |
| Ileus Paralytic |
6.0% |
| Osteonecrosis |
5.4% |
| White Blood Cell Count Decreased |
5.4% |
| Exposure During Pregnancy |
4.8% |
| Febrile Neutropenia |
4.8% |
| Vomiting |
4.2% |
| Death |
3.0% |
| Embolism Venous |
3.0% |
| Neuropathy Peripheral |
3.0% |
| Renal Impairment |
3.0% |
| Tumour Lysis Syndrome |
3.0% |
| Acute Myeloid Leukaemia |
2.4% |
| Maternal Exposure During Pregnancy |
2.4% |
| Neutropenia |
2.4% |
| Pneumonia |
2.4% |
|
| Concomitant |
| Breast Cancer |
18.5% |
| Product Used For Unknown Indication |
13.4% |
| Breast Cancer Metastatic |
9.6% |
| Non-hodgkin's Lymphoma |
7.4% |
| Plasma Cell Myeloma |
6.2% |
| Diffuse Large B-cell Lymphoma |
5.8% |
| Chemotherapy |
5.4% |
| Acute Lymphocytic Leukaemia |
4.1% |
| Breast Cancer Female |
3.9% |
| Prophylaxis |
3.6% |
| Metastases To Bone |
3.2% |
| Multiple Myeloma |
3.2% |
| B-cell Lymphoma |
2.7% |
| Angioimmunoblastic T-cell Lymphoma |
2.6% |
| Lymphoma |
2.2% |
| Hodgkin's Disease |
2.1% |
| Hypertension Arterial |
1.9% |
| B Precursor Type Acute Leukaemia |
1.5% |
| Depression |
1.4% |
| Premedication |
1.4% |
|
| Vomiting |
13.6% |
| White Blood Cell Count Decreased |
10.6% |
| Disease Progression |
9.8% |
| Weight Decreased |
8.3% |
| Wound |
7.6% |
| Death |
6.8% |
| Myocardial Infarction |
4.5% |
| Pyrexia |
4.5% |
| Pneumonia |
3.8% |
| Sepsis |
3.8% |
| Thrombocytopenia |
3.8% |
| Endometrial Cancer Metastatic |
3.0% |
| Exposure During Pregnancy |
3.0% |
| Nausea |
3.0% |
| Febrile Neutropenia |
2.3% |
| Ileus Paralytic |
2.3% |
| No Adverse Event |
2.3% |
| Pleural Effusion |
2.3% |
| Respiratory Failure |
2.3% |
| Tumour Marker Increased |
2.3% |
|
